Cecilia Low Wang, endocrinologist, delivers the bad news on the University of Colorado Health blog: "Whatever you were treating is likely to recur." The New York Times reports a sudden stop can cause a sudden rise in a patient's glucose levels
However, there are many potential off-label uses for the drug that could be the key to solving some of the worlds most pernicious and difficult-to-treat diseases, like obesity and addiction
The drugmaker earlier this year launched the direct-to-consumer pharmacy, offering Wegovy, its in-demand weight loss drug, for $499 a month
Diabetes over weight-loss narrative - Unlike the global focus on obesity, Indias opportunity lies primarily in better diabetes management and complication prevention, a far larger clinical and economic burden here
These findings highlight an important translational potential for MC4R agonists as a new therapeutic approach to treat MI and slow/halt HF progression after cardiac ischemia
We are not a pharmacy, healthcare provider, or medical supplier
